Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb, multi-center clinical study of BPZE1 versus Boostrix

Trial Profile

A Phase IIb, multi-center clinical study of BPZE1 versus Boostrix

Planning
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 22 May 2018

At a glance

  • Drugs BPZE 1 (Primary) ; DTaP vaccine
  • Indications Pertussis
  • Focus Therapeutic Use
  • Sponsors ILiAD Biotechnologies
  • Most Recent Events

    • 22 May 2018 New trial record
    • 15 May 2018 According to an ILiAD Biotechnologies media release, the company announced submission to the FDA of a Company-sponsored Phase 2b IND that is intended to initiate after analysis of 1-month immunological data from the NIAID sponsored study (CTP-700286548).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top